World Library  
Flag as Inappropriate
Email this Article

Follicle-stimulating hormone receptor

Article Id: WHEBN0005746828
Reproduction Date:

Title: Follicle-stimulating hormone receptor  
Author: World Heritage Encyclopedia
Language: English
Subject: Antigonadotropin, Prolactin receptor, Follicle-stimulating hormone, Growth hormone receptor, Bradykinin receptor
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Follicle-stimulating hormone receptor

Follicle stimulating hormone receptor
PDB rendering based on 4AY9.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; FSHR1; FSHRO; LGR1; ODG1
External IDs IUPHAR: ChEMBL: GeneCards:
RNA expression pattern
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

The follicle-stimulating hormone receptor or FSH receptor (FSHR) is a transmembrane receptor that interacts with the follicle-stimulating hormone (FSH) and represents a G protein-coupled receptor (GPCR). Its activation is necessary for the hormonal functioning of FSH. FSHRs are found in the ovary, testis, and uterus.

Contents

  • FSHR gene 1
  • Receptor structure 2
  • Ligand binding and signal transduction 3
    • Phosphorylation by cAMP-dependent protein kinases 3.1
  • Action 4
  • Receptor regulation 5
    • Upregulation 5.1
    • Desensitization 5.2
    • Downregulation 5.3
    • Modulators 5.4
  • FSH abnormalities 6
  • History 7
  • See also 8
  • References 9
  • Further reading 10
  • External links 11

FSHR gene

The gene for the FSHR is found on chromosome 2 p21 in humans. The gene sequence of the FSHR consists of about 2,080 nucleotides.[1]

Receptor structure

The seven transmembrane α-helix structure of a G protein-coupled receptor such as FSHR

The FSHR consists of 695 amino acids and has a molecular mass of about 76 kDa.[1] Like other GPCRs, the FSH-receptor possesses seven membrane-spanning domains or transmembrane helices.

  • The extracellular domain of the receptor contains 11 leucine-rich repeats and is glycosylated. It has two subdomains, a hormone-binding subdomain followed by a signal-specificity subdomain.[2] The hormone-binding subdomain is responsible for the high-affinity hormone binding, and the signal-specificity subdomain, containing a sulfated tyrosine at position 335 (sTyr) in a hinge loop, is required for the hormone activity.[3]
  • The transmembrane domain contains two highly conserved cysteine residues that build disulfide bonds to stabilize the receptor structure. A highly conserved Asp-Arg-Tyr triplet motif is present in GPCR family members in general and may be of importance to transmit the signal. In FSHR and its closely related other glycoprotein hormone receptor members (LHR and TSHR), this conserved triplet motif is a variation Glu-Arg-Trp sequence.[4]

Ligand binding and signal transduction

Upon initial binding to the LRR region of FSHR, FSH reshapes its conformation to form a new pocket. FSHR then inserts its sulfotyrosine from the hinge loop into the pockets and activates the 7-helical transmembrane domain.[2] This event leads to a transduction of the signal that activates the G protein that is bound to the receptor internally. With FSH attached, the receptor shifts conformation and, thus, mechanically activates the G protein, which detaches from the receptor and activates the cAMP system.

It is believed that a receptor molecule exists in a conformational equilibrium between active and inactive states. The binding of FSH to the receptor shifts the equilibrium between active and inactive receptors. FSH and FSH-agonists shift the equilibrium in favor of active states; FSH antagonists shift the equilibrium in favor of inactive states. For a cell to respond to FSH, only a small percentage (~1%) of receptor sites need to be activated.

Phosphorylation by cAMP-dependent protein kinases

Cyclic AMP-dependent protein kinases (protein kinase A) are activated by the signal chain coming from the G protein (that was activated by the FSH-receptor) via adenylate cyclase and cyclic AMP (cAMP).
These protein kinases are present as tetramers with two regulatory units and two catalytic units. Upon binding of cAMP to the regulatory units, the catalytic units are released and initiate the phosphorylation of proteins, leading to the physiologic action. The cyclic AMP-regulatory dimers are degraded by phosphodiesterase and release 5’AMP. DNA in the cell nucleus binds to phosphorylated proteins through the cyclic AMP response element (CRE), which results in the activation of genes.[1]

The signal is amplified by the involvement of cAMP and the resulting phosphorylation. The process is modified by prostaglandins. Other cellular regulators are participate are the intracellular calcium concentration modified by phospholipase, nitric acid, and other growth factors.

The FSH receptor can also activate the extracellular signal-regulated kinases (ERK).[5] In a feedback mechanism, these activated kinases phosphorylate the receptor. The longer the receptor remains active, the more kinases are activated, the more receptors are phosphorylated.

Action

In the ovary, the FSH receptor is necessary for follicular development and expressed on the granulosa cells.[1]

In the male, the FSH receptor has been identified on the Sertoli cells that are critical for spermatogenesis.[6]

The FSHR is expressed during the luteal phase in the secretory endometrium of the uterus.[7]

FSH receptor is selectively expressed on the surface of the blood vessels of a wide range of carcinogenic tumors.[8]

Receptor regulation

Upregulation

Upregulation refers to the increase in the number of receptor site on the membrane. Estrogen upregulates FSH receptor sites. In turn, FSH stimulates granulosa cells to produce estrogens. This synergistic activity of estrogen and FSH allows for follicle growth and development in the ovary.

Desensitization

The FSHR become desensitized when exposed to FSH for some time. A key reaction of this downregulation is the phosphorylation of the intracellular (or cytoplasmic) receptor domain by protein kinases. This process uncouples Gs protein from the FSHR. Another way to desensitize is to uncouple the regulatory and catalytic units of the cAMP system.

Downregulation

Downregulation refers to the decrease in the number of receptor sites. This can be accomplished by metabolizing bound FSHR sites. The bound FSH-receptor complex is brought by lateral migration to a "coated pit," where such units are concentrated and then stabilized by a framework of clathrins. A pinched-off coated pit is internalized and degraded by lysosomes. Proteins may be metabolized or the receptor can be recycled. Use of long-acting agonists will downregulate the receptor population.

Modulators

Antibodies to FSHR can interfere with FSHR activity.

FSH abnormalities

Some patients with ovarian hyperstimulation syndrome may have mutations in the gene for FSHR, making them more sensitive to gonadotropin stimulation.[9]

Women with 46 XX gonadal dysgenesis experience primary amenorrhea with hypergonadotropic hypogonadism. There are forms of 46 xx gonadal dysgenesis wherein abnormalities in the FSH-receptor have been reported and are thought to be the cause of the hypogonadism.[10]

Polymorphism may affect FSH receptor populations and lead to poorer responses in infertile women receiving FSH medication for IVF.[11]

History

Alfred G. Gilman and Martin Rodbell received the 1994 Nobel Prize in Medicine and Physiology for the discovery of the G Protein System.

See also

References

  1. ^ a b c d Simoni M, Gromoll J, Nieschlag E (December 1997). "The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology". Endocr. Rev. 18 (6): 739–73.  
  2. ^ a b Jiang X, Liu H, Chen X, Chen PH, Fischer D, Sriraman V, Yu HN, Arkinstall S, He X (July 2012). "Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor". Proc Natl Acad Sci U S A 109 (31): 12491–6.  
  3. ^ Costagliola S, Panneels V, Bonomi M, Koch J, Many MC, Smits G, Vassart G (Feb 2002). "Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors". EMBO J 21 (4): 504–13.  
  4. ^ Jiang X, Dias JA, He X (January 2014). "Structural biology of glycoprotein hormones and their receptors: Insights to signaling". Mol Cell Endocrinol 382 (1): 424 – 451.  
  5. ^ Piketty V, Kara E, Guillou F, Reiter E, Crepieux P (2006). "Follicle-stimulating hormone (FSH) activates extracellular signal-regulated kinase phosphorylation independently of beta-arrestin- and dynamin-mediated FSH receptor internalization". Reprod. Biol. Endocrinol. 4: 33.  
  6. ^ Asatiani K, Gromoll J, Eckardstein SV, Zitzmann M, Nieschlag E, Simoni M (June 2002). "Distribution and function of FSH receptor genetic variants in normal men". Andrologia 34 (3): 172–6.  
  7. ^ La Marca A, Carducci Artenisio A, Stabile G, Rivasi F, Volpe A (December 2005). "Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium". Gynecol. Endocrinol. 21 (6): 303–6.  
  8. ^ Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont GX, Hai MT, Ghinea N (October 2010). "Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels". N Engl J Med 363 (17): 1621–1630.  
  9. ^ Delbaere A, Smits G, De Leener A, Costagliola S, Vassart G (April 2005). "Understanding ovarian hyperstimulation syndrome". Endocrine 26 (3): 285–90.  
  10. ^ Aittomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila EM, Lehväslaiho H, Engel AR, Nieschlag E, Huhtaniemi I, de la Chapelle A (September 1995). "Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure". Cell 82 (6): 959–68.  
  11. ^ Loutradis D, Patsoula E, Minas V, Koussidis GA, Antsaklis A, Michalas S, Makrigiannakis A (April 2006). "FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs". J. Assist. Reprod. Genet. 23 (4): 177–84.  

Further reading

  • de la Chapelle A (1993). "Disease gene mapping in isolated human populations: the example of Finland.". J. Med. Genet. 30 (10): 857–65.  
  • Amsterdam A, Hanoch T, Dantes A; et al. (2003). "Mechanisms of gonadotropin desensitization.". Mol. Cell. Endocrinol. 187 (1–2): 69–74.  
  • Simoni M, Nieschlag E, Gromoll J (2003). "Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction". Hum. Reprod. Update 8 (5): 413–21.  
  • Delbaere A, Smits G, Olatunbosun O; et al. (2004). "New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?". Hum. Reprod. 19 (3): 486–9.  
  • Bose CK (2005). "Role of nerve growth factor and FSH receptor in epithelial ovarian cancer". Reprod. Biomed. Online 11 (2): 194–7.  
  • Wunsch A, Sonntag B, Simoni M (2007). "Polymorphism of the FSH receptor and ovarian response to FSH". Ann. Endocrinol. (Paris) 68 (2–3): 160–6.  
  • Kelton CA, Cheng SV, Nugent NP; et al. (1993). "The cloning of the human follicle stimulating hormone receptor and its expression in COS-7, CHO, and Y-1 cells". Mol. Cell. Endocrinol. 89 (1–2): 141–51.  
  • Tilly JL, Aihara T, Nishimori K; et al. (1992). "Expression of recombinant human follicle-stimulating hormone receptor: species-specific ligand binding, signal transduction, and identification of multiple ovarian messenger ribonucleic acid transcripts". Endocrinology 131 (2): 799–806.  
  • Gromoll J, Gudermann T, Nieschlag E (1992). "Molecular cloning of a truncated isoform of the human follicle stimulating hormone receptor". Biochem. Biophys. Res. Commun. 188 (3): 1077–83.  
  • Minegishi T, Nakamura K, Takakura Y; et al. (1991). "Cloning and sequencing of human FSH receptor cDNA". Biochem. Biophys. Res. Commun. 175 (3): 1125–30.  
  • Gromoll J, Ried T, Holtgreve-Grez H; et al. (1994). "Localization of the human FSH receptor to chromosome 2 p21 using a genomic probe comprising exon 10". J. Mol. Endocrinol. 12 (3): 265–71.  
  • Gromoll J, Dankbar B, Gudermann T (1994). "Characterization of the 5' flanking region of the human follicle-stimulating hormone receptor gene". Mol. Cell. Endocrinol. 102 (1–2): 93–102.  
  • Rousseau-Merck MF, Atger M, Loosfelt H; et al. (1993). "The chromosomal localization of the human follicle-stimulating hormone receptor gene (FSHR) on 2p21-p16 is similar to that of the luteinizing hormone receptor gene". Genomics 15 (1): 222–4.  
  • Jiang X, Dreano M, Buckler DR; et al. (1996). "Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions". Structure 3 (12): 1341–53.  
  • Aittomäki K, Herva R, Stenman UH; et al. (1996). "Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene". J. Clin. Endocrinol. Metab. 81 (10): 3722–6.  
  • Tapanainen JS, Aittomäki K, Min J; et al. (1997). "Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility". Nat. Genet. 15 (2): 205–6.  
  • Kotlar TJ, Young RH, Albanese C; et al. (1997). "A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors". J. Clin. Endocrinol. Metab. 82 (4): 1020–6.  

External links

  • "Glycoprotein Hormone Receptors: FSH". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. 
  • GRIS: Glycoprotein-hormone Receptor Information System
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.